ProQR Therapeutics’ (PRQR) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research note released on Friday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on the stock. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Monday, March 10th. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Finally, Oppenheimer started coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

ProQR Therapeutics Stock Performance

NASDAQ PRQR opened at $1.69 on Friday. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62. The stock has a market cap of $138.04 million, a P/E ratio of -5.28 and a beta of 0.24. The stock has a 50 day simple moving average of $2.25 and a two-hundred day simple moving average of $2.62.

Institutional Trading of ProQR Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in PRQR. Jane Street Group LLC purchased a new position in ProQR Therapeutics during the fourth quarter valued at $30,000. Invesco Ltd. bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at $32,000. Alpine Global Management LLC purchased a new position in shares of ProQR Therapeutics in the 4th quarter worth about $39,000. Two Sigma Securities LLC purchased a new position in shares of ProQR Therapeutics in the 4th quarter worth about $40,000. Finally, ADAR1 Capital Management LLC bought a new position in ProQR Therapeutics in the 4th quarter worth about $54,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).